Poster discussion hub abstracts remained significant when sub-analysed for males (p=0.036) and for females (p=0.013). In addition neonatal gender, maternal height, weight before pregnancy and weight at term were also significantly correlated with NHC (p-values 0.014, 0.004, 0.03, 0.01 respectively). In a multivariate analysis, MHC and neonatal gender were the only significant independent predictors. However the model could explain only 8.6% of the NHC variability. Conclusions: NHC is influenced by maternal body habitus and neonatal gender. The low R 2 of the prediction model implies that head growth during fetal life is influenced by other factors.
Objectives:
To estimate the impact of low-dose aspirin started in the first trimester in twin pregnancies. Methods: We performed a randomised trial of women with twins between 10 and 14 weeks of gestation. They were randomised to 81 mg of aspirin at bedtime or an equivalent placebo from randomisation (<14 weeks) until 36 weeks'. Primary outcome was the birthweight of live infants. Secondary outcomes include very low birth weight (VLBW) neonates (<1500 grams); pre-eclampsia; and aspirin non-responsiveness defined by a normal platelet aggregation test (PFA-100<145). We aimed to recruit 50 participants (100 fetuses) to have the power to detect a difference of 400 grams between the groups based on a previous meta-analysis. Results: Fifty participants were randomised at a mean gestational age of 13.0±0.6 weeks and complete follow-up was obtained for all. We observed 2 cases of PE in women in the aspirin group and no case in the placebo group (p=0.49). Forty-seven newborns alive in the aspirin group were compared to 48 newborns alive in the placebo group: no significant difference were observed for our primary outcome (aspirin: 2385±529 grams vs placebo: 2224±706 grams, p=0.21) and VLBW (6% vs 15%, p=0.20). Of note, 16/25 (65%) of the participants in the aspirin group had a normal PFA-100, including the two cases of pre-eclampsia and the additional case of gestational hypertension. Conclusions: We observed no significant impact of 81 mg of aspirin started in the first trimester on birthweight, VLBW and pre-eclampsia. However, the majority of women with twin pregnancies were ''non-responsive'' to aspirin at 81 mg daily according to the platelet aggregation test. Subsequent trials evaluating the impact of aspirin on twin pregnancies should use more than 81 mg of aspirin.
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The relationship between cardiomegaly and global strain in fetuses with intrauterine growth restriction (IUGR) Objectives: During the screening examination of the fetal heart cardiomegaly can be identified by computing the area of the 4-chamber view (4CV). The purpose of this study was to compare the relationship between cardiomegaly of the 4CV and global strain of the right (RV) and left (LV) ventricles. Methods: 30 fetuses with growth restriction (EFW < 10th centile) were evaluated between 25 and 37 weeks of gestation. The 4CV was identified at end-diastole and the longest basal-apical and transverse lengths were measured, followed by computation of the area. Using previously published criteria, cardiomegaly was defined as an area >90% for the estimated fetal weight (EFW). Global strain was computed using speckle tracking software in which the endocardial length was measured at end-diastole and end-systole from the RV and LV. From these measurements the global strain was computed as follows: [(end-systolic length-end-diastolic length)/end diastolic length) x 100] . Abnormal global strain was defined as values >90th centile derived from Z score computation using data from 200 control fetuses. Results: The mean global strain for the RV was -23 (3.9) and the LV -23 (3.7). Cardiomegaly was present in 46% (14/30) of fetuses with IUGR. Fifty percent of fetuses with cardiomegaly (7/14) had abnormal global strain of the LV, and 64% (9/14) had abnormal global strain of the RV. Abnormal global strain of either the right and/or left ventricles was present in 71% (10/14). Conclusions: A simple method to detect cardiomegaly is to compute the area of the 4CV. If abnormally increased in size, evaluation of global strain of the RV and LV should be considered as it reflects early ventricular dysfunction. While global strain was computed in this study using speckle-tracking software, the end-diastolic and end-systolic endocardial lengths of the ventricular chambers can be measured using generic length measurement software present on most ultrasound machines. From these measurements the global strain can be computed.
